|The War Room If you whine to me or any other mods , your email or PM will be posted in the War Room. PLease keep that in mind|
| ||LinkBack||Thread Tools|
Government Interference in Pharmaceutical Markets Costs Canadians $2 billion to $5 billion Annually
Toronto, ON - Generic drugs are on average 78 percent more expensive in Canada than in the United States, according to a new study Canada's Drug Price Paradox: The Unexpected Losses Caused by Government Interference in Pharmaceutical Markets, released today by The Fraser Institute.
The study calculates that Canadians could save between $2 billion and $5 billion annually if governments allowed the pharmaceutical market in Canada to be as competitive as the US market.
“Governments claim that price regulations reduce drug costs for Canadians,” said Brett Skinner, author of the study and director of pharmaceutical and health policy research at the Institute. “Yet the data show that Canadians actually pay more than they should for non-patented drugs—especially for generics, because government policies that were supposed to make drugs cheaper, instead reduce competition and drive up prices.”
US prices for generic drugs are lower because the American market has more generic manufacturers competing for sales, which leads to lower prices and higher voluntary rates of generic drug use in the United States. By contrast, only a few firms with little serious competition dominate the Canadian generic market. This leads to inflated prices and lower rates of generic use.
The study finds that only two generic companies accounted for 68 percent of all prescriptions dispensed among the 100 top selling generics in 2003, and only five companies accounted for 95 percent. The data also shows that Canada’s generic market is divided up into individual product monopolies on pharmacy shelves, often with only one or two companies taking all the sales for individual products, while not competing for sales of other products.
“If our market were as competitive as the US, we could expect our prices for generic drugs to fall at least as low as US levels and our voluntary use of generic drugs to increase to US levels, resulting in significant economic savings,” noted Skinner.
The study suggests that price controls and other policies distort the pharmaceutical market, reduce competition and harm Canadian consumers by causing inflated prices for non-patented drugs, and suggests that Canadians would be better off if governments repealed such policies.
“Government pharmaceutical policy is simply failing to provide better outcomes than competitive markets could,” Skinner concluded.
Ironically, the study finds that Canadians have little to fear from the removal of price controls on patented drugs because market prices would not be much different from current government-imposed prices anyway.
The data show that market-priced off-patent brand drugs sell at nearly the same discounts as price-controlled patented brand drugs (42 to 43 percent below US prices) suggesting that the removal of price controls would not lead to US-level prices in Canada.
“Governments cannot justify intervening in pharmaceutical markets through price controls based on the belief that market prices would be too high. In a competitive market, lower average Canadian incomes will keep prices low relative to prices in higher income markets like the United States,” Skinner said.
- 30 -
Established in 1974, The Fraser Institute is an independent public policy
organization with offices in Vancouver, Calgary, and Toronto.
Full Publication Here (PDF)